natgillin/translations-raw huggingface dataset:
The rates per hundred patient-years of confirmed complicated and uncomplicated upper GI clinical events (perforations, ulcers and bleeds (PUBs)) were 0.67 (95% CI 0.57, 0.77) with etoricoxib and 0.97 (95% CI 0.85, 1.10) with diclofenac, yielding a relative risk of 0.69 (95% CI 0.57, 0.83). 
Deleža resnih trombotičnih dogodkov sta bila: pri etorikoksibu 1,25 dogodka na 100 bolnikov-let, pri diklofenaku pa 1,15 dogodka na 100 bolnikov-let (relativno tveganje 1,07, 95 % interval zaupanja: 0,65 %, 1,74 %).
Etoricoxib was included in previous CHMP referrals on the safety of COX-2 selective inhibitors in which concluded in 2004 and 2005. 
CHMP je o kardiovaskularni varnosti razpravljal na svoji seji februarja 2005.
Metabolism 
Tableta
Ear and labyrinth disorders: Uncommon: tinnitus, vertigo. 
Ušesne bolezni, vključno z motnjami labirinta: Občasne: tinitus.
Concomitant administration of etoricoxib with doses of acetylsalicylic acid above those for cardiovascular prophylaxis or with other NSAIDs is not recommended (see sections 5.1 and 4.4. 
Sočasnega zdravljenja z etorikoksibom in acetilsalicilno kislino v odmerkih, večjih od tistih za preprečevanje srčno-žilnih bolezni, ali z drugimi NSAR-i ne priporočamo.
CONDITIONS OF THE MARKETING AUTHORISATION 
PODLAGA ZA DOPOLNILO DOVOLJENJA ZA PROMET
There was no significant difference between etoricoxib and diclofenac in the rate of complicated events. 
Med etorikoksibom in placebom ni bilo statistično značilne razlike.
In the study, the incidence of discontinuations due to hypertension-related adverse events was statistically significantly higher for etoricoxib than for diclofenac. 
Pojavnost kliničnih dogodkov v prebavilih, ki so pripeljali do prekinitve zdravljenja, je bila statistično pomembno manjša pri etorikoksibu kot pri diklofenaku (7,1 % proti 9,1 %).
As a consequence, the CHMP has recommended to maintain the Marketing Authorisation for all medicinal products containing 90 mg of etoricoxib referred to in Annex I of the Opinion and to amend the relevant sections of the summary of product characteristics and package leaflet, as set out in Annex III of the Opinion in accordance with Article 31 (2) of Directive 2001/83/EC, as amended. 
V zvezi z razpravo Odbora za zdravila za uporabo v humani medicini (CHMP) na plenarni seji oktobra 2004 je Evropska komisija priporočila, da se za to javno zdravstveno vprašanje o vseh vidikih kardiovaskularne varnosti, vključno s trombotičnimi dogodki in kardiorenalnimi dogodki, sproži napotitveni postopek Skupnosti v skladu z 31. členom Direktive 2001/83/ES z vsemi dodatki za zdravila, odobrena po decentraliziranem postopku, in vsebujejo celekoksib, etorikoksib in lumirakoksib ter revizijski postopek v skladu z 18. členom Uredbe Sveta (EGS) št. 2309/93 z vsemi dodatki za zdravila, odobrena po centraliziranem postopku, in vsebujejo celekoksib (Onsenal), parekoksib (Dynastat/Rayzon) in valdekoksib (Bextra/Valdyn).
The EDGE study included 7111 OA patients treated with a dose of etoricoxib 90 mg daily (1.5 times the dose recommended for OA) or diclofenac 150 mg daily for a mean period of 9.1 months (maximum 16.6 months, median 11.4 months). 
V raziskavi s približno 7.100 bolniki z osteoartrozo so primerjali prenašanje etorikoksiba 90 mg (1,5kratni priporočeni odmerek pri OA) in diklofenaka 150 mg v prebavilih.
60 mg dark green, apple-shaped, biconvex film coated tablets marked ‘ARCOXIA 60' on one side and ‘200' on the other. 
60 mg tablete: Zelene, bikonveksne tablete v obliki jabolka, z oznako "447" na eni strani ter "MSD" na drugi strani.
The rate per hundred patient-years was 0.22 on etoricoxib and 1.84 for diclofenac (p-value was <0.001 for etoricoxib vs. diclofenac). 
Deleža ishemičnih možganskih kapi sta bila 0,14 proti 0,23 na 100 bonikov-let za etorikoksib oz. diklofenak.
In rabbits, a treatment related increase in cardiovascular malformations was observed at exposure levels below the clinical exposure at the daily human dose (90 mg). 
Pri podganah in kuncih niso ugotovili vpliva na zarodek/plod pri sistemski izpostavitvi, enaki ali manjši od priporočenega dnevnega odmerka pri človeku (90 mg).
MEDAL Program Gastrointestinal Safety Results: 
V raziskavi so prišli še do naslednjih ugotovitev v zvezi z varnostjo:
The CHMP concluded on 26 June 2008 that the data confirm the known relatively adverse renovascular safety profile of etoricoxib (hypertension, oedema and congestive heart failure), but similar CV thrombotic risk as diclofenac and some degree of upper GI safety advantage over naproxen and diclofenac (though no particular lower GI safety advantage). 
- novih podatkov, ki jih je za rofekoksib prispevala klinična raziskava APPROVe in ki kažejo tveganje za trombotične kardiovaskularne dogodke, - podatkov za celekoksib iz raziskave APC, ki so nakazali povečanje tveganja hudih kardiovaskularnih dogodkov, ki so odvisni od odmerka, - podatkov za valdekoksib in parekoksib iz raziskav CABG (Coronary Artery Bypass Graft) in CABG II, ki kažejo višjo stopnjo hudih kardiovaskularnih tromboembolijskih dogodkov v skupinah bolnikov, ki so se zdravili s parekoksibom/valdekoksibom, v primerjavi s skupino bolnikov, ki je prejemala placebo, - podatkov za etorikoksib iz raziskave EDGE ter analiz združenih podatkov iz drugih kliničnih preizkušanj, ki nakazujejo povezavo z večjim tveganjem za trombotične dogodke v primerjavi z naproksenom; - podatkov za lumirakoksib iz raziskave Target, ki nakazujejo majhno povečanje trombotičnih dogodkov (zlasti miokardnega infarkta) v primerjavi z naproksenom,
30 mg: lactose 1.4 mg 60 mg: lactose 2.8 mg 90 mg: lactose 4.2 mg 120 mg: lactose 5.6 mg 
60 mg: zloženke po 7 tablet: 5363-I-646/02 zloženke po 14 tablet: 5363-I-647/02 zloženke po 28 tablet: 5363-I-648/02 90 mg:
Cardiorenal Events: 
Srčno-žilni podatki:
In the pooled MEDAL Program, 0.3% of patients on etoricoxib and 2.7% of patients on diclofenac discontinued due to hepatic-related adverse experiences. 
Pojavnost prekinitev zaradi edemov pa je bila 0,9 % za etorikoksib, za diklofenak pa 0,7 %.
In patients with moderate hepatic dysfunction (Child-Pugh score 7-9), regardless of indication, the dose of 60 mg every other day should not be exceeded; administration of 30 mg once daily can also be considered. 
Pri bolnikih z zmerno motnjo delovanja jeter (lestvica po Child-Pughu 7-9) ne smemo prekoračiti priporočenega odmerka 60 mg vsak drugi dan. Klinične izkušnje so še posebej omejene pri bolnikih z zmerno motnjo delovanja jeter, zato svetujemo previdnost.
Merck, Sharp & Dohme Ltd Hertfordshire Road Hoddesdon 
Merck Sharp & Dohme Ltd. Šmartinska cesta 140
PRT 
Presnova
120 mg pale-green, apple-shaped, biconvex film coated tablets marked ‘ARCOXIA 120' on one side and ‘204' on the other. 
Svetlo zelene, bikonveksne tablete v obliki jabolka, z oznako "541" na eni strani ter "MSD" na drugi strani.
There have been reports of acute overdosage with etoricoxib, although adverse experiences were not reported in the majority of cases. 
V kliničnih raziskavah niso poročali o primerih prevelikega odmerjanja.
The upper GI benefit for etoricoxib compared with diclofenac was not statistically significant in patients taking concomitant low-dose aspirin (approximately 33% of patients). 
Neželeni učinki v jetrih: Etorikoksib je bil v primerjavi z diklofenakom povezan s statistično pomembno manjšim deležem prekinitev zdravljenja predvsem zaradi povišanj vrednosti testov jetrne funkcije (0,3 % proti 5,2 %).
The rate of confirmed thrombotic cardiovascular serious adverse events (consisting of cardiac, cerebrovascular, and peripheral vascular events) was comparable between etoricoxib and diclofenac, and data are summarized in the table below. 
Deleži potrjenih perforacij, razjed in krvavitev zgornjih prebavil so bili pri etorikoksibu in diklofenaku enaki (1,11 dogodka na 100 bolnikov-let).
If you are using <Etoricoxib>, you must not breastfeed. 
Ženske, ki jemljejo etorikoksib, ne smejo dojiti.
Patients with a recent history of myocardial infarction, coronary artery bypass grafting or percutaneous coronary intervention within 6 months preceding enrollment were excluded. 
Vpliv etorikoksiba, celekoksiba in naproksena na izločanje natrija v urinu je bil v 2 tednih zdravljenja podoben.
People with liver problems 
Učinki na jetra
In the absence of an increase in therapeutic benefit, other therapeutic options should be considered. 
Če se krni tlak pomembno zviša, je treba razmisliti o nadomestnem zdravljenju.
POSSIBLE SIDE EFFECTS 
Učinki na prebavila
In March 2006, the marketing authorisation holders (MAH) for etoricoxib submitted an application to extend the licensed indication to include treatment of ankylosing spondylitis (AS), at a recommended daily dose of 90mg. 
Septembra 2004 je imetnik dovoljenja za promet z rofekoksibom (selektivnim zaviralcem Cox-2) obvestil Evropsko agencijo za zdravila, da so podatki iz novega kliničnega preizkušanja (APPROVe) rofekoksiba pokazali tveganje za trombotične kardiovaskularne dogodke.
Blisters: Store in the original package in order to protect from moisture. 
Pretisni omoti: Shranjujte v originalni ovojnini.
However, the rate of these events was higher in patients receiving etoricoxib compared with those receiving naproxen 500 mg twice daily. 
Tveganje za te opazovane dogodke je bilo približno za 50 % manjše pri bolnikih, ki so se zdravili z etorikoksibom (60, 90 ali 120 mg dnevno), v primerjavi z bolniki, ki so dobivali naproksen 500 mg dvakrat na dan ali diklofenak 50 mg trikrat na dan.
These led to updates of the product information to include class warnings on the risk of CV thrombotic, GI and severe skin reactions with COX-2 selective inhibitors. 
- Okrepljeno je opozorilo, ki poudarja, da so se pri uporabi zaviralcev COX-2 pojavile usodno hude kožne reakcije.
Paço d' Arcos 
Učinki na ledvice
A significantly lower rate of discontinuations of treatment for any clinical (e.g., dyspepsia, abdominal pain, ulcer) GI adverse event was observed with etoricoxib compared with diclofenac within each of the three component studies of the MEDAL Program. 
Prenašanje in varnost v prebavilih: Etorikoksib je bil v primerjavi z diklofenakom povezan s statistično pomembno manjšo pojavnostjo prekinitev zdravljenja pri bolnikih zaradi vnaprej opredeljenega sestavljenega končnega dogodka: kliničnih neželenih učinkov v prebavilih in laboratorijskih neželenih učinkov v povezavi s povišanimi vrednostmi testov jetrne funkcije.
The CHMP therefore recommends the strengthening of the contraindication in hypertensive patients and alerts prescribers that blood pressure needs to be monitored, especially within 2 weeks of treatment initiation. 
- Dodano je opozorilo v zvezi s hipertenzijo in spremljanjem krvnega tlaka med zdravljenjem z etorikoksibom.
The CHMP reviewed the data submitted by the marketing authorisation holders from clinical trials, drug utilisation studies and spontaneous reporting of adverse drug reactions. 
Nadaljnji ukrepi imetnika dovoljenja za promet z zdravilom Glede na zahteve CHMP-ja se je imetnik dovoljenja za promet strinjal, da bo izvedel nadaljnje ukrepe kot so navedeni spodaj
Therefore, France sent a notification that was received by the EMEA on 19 September 2007 and a referral under Article 31 of Directive 2001/83/EC, as amended was started on 20 September 2007. 
Nujen varnostni ukrep se je začel 16. februarja 2005 in zaključil 17. februarja 2005.
The cardiorenal results for EDGE and EDGE II were consistent with those described for the MEDAL Study. 
Imetnik dovoljenja za promet se zavezuje, da bo obvestil CHMP o izidu študij MEDAL in EDGE II o kardiovaskularni in gastrointestinalni varnosti po njunem zaključku in ustrezno predložil potrebne posodobljene podatke.
List of the names, pharmaceutical form, strength of the medicinal product(s), route of administration, marketing authorisation holders in the member states 
Priloga I Seznam imen, farmacevtskih oblik, jakosti zdravil, poti uporabe, imetnikov dovoljenj za promet v državah članicah
Marketing authorisaton holder 
Imetnik dovoljenja za promet
Product name 
Ime
Withdrawal period 
Lastniško ime
This is a summary of the European public assessment report (EPAR) for Raxone. 
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Raxone.
European Medicines Agency will review any new information that becomes available and this summary will be updated as necessary. 
Evropska agencija za zdravila bo vsako leto ponovno pregledala vse nove podatke, ki bodo na voljo, in posodobila povzetek glavnih značilnosti zdravila, če bo potrebno.
What measures are being taken to ensure the safe and effective use of Raxone? 
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Raxone?
The Agency's Committee for Medicinal Products for Human Use (CHMP) decided that the benefits of Raxone are greater than its risks and recommended that it be approved for use in the EU. 
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da so koristi zdravila Raxone večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
Patients affected by LHON have mutations (defects) in the genetic material of mitochondria. 
Bolniki z LKON imajo mutacije (okvare) v genskem materialu mitohondrijev.
The main measure of effectiveness was improvement in vision, mostly based on the numbers of letters patients were able to read on a standard eye test chart. 
Glavno merilo učinkovitosti je bilo izboljšanje vida, ki je večinoma temeljilo na številu črk, ki so jih lahko bolniki prebrali s standardnega kartona za preverjanje vida.
Raxone is available as 150 mg tablets, and the recommended dose is two tablets taken three times a day with food. 
Zdravilo Raxone je na voljo v obliki 150-miligramskih tablet, priporočeni odmerek pa je dve tableti trikrat na dan, skupaj s hrano.
Raxone has been authorised under ‘exceptional circumstances'. 
Zdravilo Raxone je pridobilo dovoljenje za promet „v izjemnih okoliščinah“.
Furthermore, some patients who were classified as ‘off chart' (unable to read any letters on the chart) at the beginning of the study were able to read at least one line during the eye test after treatment, and this was also considered clinically important. 
Poleg tega so lahko bolniki, ki so bili na začetku študije razvrščeni kot „zunaj kartona“ (niso bili sposobni prebrati nobenih črk s kartona), prebrali vsaj eno vrstico med preverjanjem vida po zdravljenju, kar je bilo klinično pomembno.
A risk management plan has been developed to ensure that Raxone is used as safely as possible. 
Za zagotovitev čim varnejše uporabe zdravila Raxone je bil pripravljen načrt obvladovanja tveganj.
The summary of the opinion of the Committee for Orphan Medicinal Products for Raxone can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/Rare disease designation. 
Povzetek mnenja Odbora za zdravila sirote o zdravilu Raxone je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
The reference medicine for Raxone is Mnesis (45 mg tablets). 
Referenčno zdravilo za zdravilo Raxone je zdravilo Mnesis (45 mg tablete).
This means that it is similar to a ‘reference medicine' containing the same active substance, but Raxone contains idebenone at a different strength. 
To pomeni, da je podobno referenčnemu zdravilu in vsebuje enako zdravilno učinkovino, vendar jo zdravilo Raxone vsebuje v drugačni jakosti.
By the end of the study, patients treated with Raxone were able to read on average 3 to 6 letters more compared with patients receiving placebo. 
Ob koncu študije so bolniki, zdravljeni z zdravilom Raxone, lahko prebrali povprečno 3 do 6 črk več kot bolniki, ki so prejemali placebo.
The Committee noted the lack of treatments for preventing or reversing the vision loss in patients with LHON. 
Odbor je izpostavil pomanjkanje oblik zdravljenja za preprečevanje ali zaustavljanje izgube vida pri bolnikih z LKON.
Other information about Raxone 
Druge informacije o zdravilu Raxone
Raxone is a ‘hybrid medicine'. 
Zdravilo Raxone je „hibridno zdravilo“.
Additionally, 30% of patients treated with Raxone (16 out of 53) had a clinically relevant recovery of vision in at least one eye, compared with 10% of patients (3 out of 29) in the placebo group. 
Prav tako je 30 % bolnikov, zdravljenih z zdravilom Raxone (16 od 53), doseglo klinično pomembno izboljšanje vida v vsaj enem očesu, pri bolnikih v skupini s placebom pa samo 10 % bolnikov (3 od 29).
Raxone is a medicine used to treat visual impairment in adults and adolescents aged 12 years and over with Leber's hereditary optic neuropathy (LHON), an inherited disease characterised by progressive loss of sight. 
Raxone je zdravilo, ki se uporablja za zdravljenje poslabšanja vida pri odraslih in mladostnikih, starih 12 let in več, z Lebrovo kongenitalno optično nevropatijo (LKON), dedno boleznijo, za katero je značilna napredujoča izguba vida.
This is because it has not been possible to obtain complete information about Raxone due to the rarity of the disease. 
Do tega je prišlo zato, ker zaradi redkosti bolezni ni bilo mogoče pridobiti vseh informacij o njem.
The active substance in Raxone, idebenone, is an anti-oxidant agent that acts on mitochondria (the structures inside cells that produce the energy necessary for cells to function). 
Zdravilna učinkovina v zdravilu Raxone, idebenon, je antioksidant, ki deluje na mitohondrije (strukture znotraj celic, ki ustvarjajo energijo, potrebno za delovanje celic).
It is not intended to provide practical advice on how to use Raxone. 
Povzetek ni namenjen zagotavljanju praktičnih nasvetov o njegovi uporabi.
For more information about treatment with Raxone, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Za več informacij o zdravljenju z zdravilom Raxone preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
Because the number of patients with Leber's hereditary optic neuropathy is low, the disease is considered ‘rare', and Raxone was designated an ‘orphan medicine' (a medicine used in rare diseases) on 15 February 2007. 
Ker je bolnikov z Lebrovo kongenitalno optično nevropatijo malo, velja ta bolezen za redko, zato je bilo zdravilo Raxone 15. februarja 2007 določeno kot „zdravilo sirota“ (zdravilo za zdravljenje redkih bolezni).
What is Raxone and what is it used for? 
Kaj je zdravilo Raxone in za kaj se uporablja?
Since Raxone has been approved under exceptional circumstances, the company that markets Raxone will conduct additional studies on the long-term effects and safety of Raxone, and will establish and maintain a registry of LHON patients treated with Raxone. 
Ker je zdravilo Raxone pridobilo dovoljenje za promet v izjemnih okoliščinah, bo družba, ki ga trži, zagotovila izvedbo dodatnih študij o dolgoročnih učinkih in varnosti zdravila Raxone ter vzpostavila in vzdrževala register bolnikov z LKON, zdravljenih z zdravilom Raxone.
Why is Raxone approved? 
Zakaj je bilo zdravilo Raxone odobreno?
Additional supportive data on the benefits of Raxone came from an expanded access program through which Raxone was made available to individual patients not participating in a clinical study, and from a case record survey, which included data from patients with LHON who did not receive any treatment. 
Dodatni podporni podatki o koristih zdravila Raxone izhajajo iz programa razširjenega dostopa, v katerem je bilo zdravilo Raxone na voljo posameznim bolnikom, ki niso sodelovali v klinični študiji, in raziskave primerov v evidenci, ki je vključila podatke bolnikov z LKON, ki niso prejeli nobenega zdravljenja.
The full EPAR and risk management plan summary for Raxone can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. 
Celotno evropsko javno poročilo o oceni zdravila (EPAR) in povzetek načrta obvladovanja tveganj za zdravilo Raxone sta na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
What benefits of Raxone have been shown in studies? 
Kakšne koristi je zdravilo Raxone izkazalo v študijah?
This means that mitochondria do not work properly to generate energy, and produce toxic forms of oxygen (free radicals) that damage nerve cells in the eye that are needed for vision. 
To pomeni, da mitohondriji niso zmožni pravilno ustvarjati energije, zato tvorijo strupene oblike kisika (proste radikale), ki poškodujejo živčne celice v očesu, potrebne za vid.
What are the risks associated with Raxone? 
Kakšna tveganja so povezana z zdravilom Raxone?
The most common side effects with Raxone (which may affect more than 1 in 10 people) are nasopharyngitis and cough; mild to moderate diarrhoea and back pain are also common (affecting up to 1 in 10 people). 
Najpogostejša neželena učinka zdravila Raxone (ki lahko prizadeneta več kot 1 osebo od 10) sta nazofaringitis in kašelj, pogosta (ki lahko prizadeneta največ 1 osebo od 10) pa sta tudi blaga do zmerna driska in bolečina v hrbtu.
Idebenone is thought to help improve production of energy by restoring mitochondrial function, thereby preventing the cellular damage and the loss of sight seen in LHON. 
Menijo, da idebenon pomaga izboljšati tvorbo energije, tako da ponovno vzpostavi delovanje mitohondrijev, kar preprečuje celično poškodbo in izgubo vida, povezano z LKON.
For the full list of all side effects and restrictions with Raxone, see the package leaflet. 
Za celoten seznam neželenih učinkov in omejitev pri uporabi zdravila Raxone glejte navodilo za uporabo.
Raxone can only be obtained with a prescription and treatment should be started and supervised by a doctor with experience in LHON. 
Izdaja zdravila Raxone je le na recept, zdravljenje pa mora začeti in nadzorovati zdravnik, ki ima izkušnje z LKON.
What information is still awaited for Raxone? 
Katere informacije o zdravilu Raxone še pričakujemo?
Raxone has been investigated in one main study involving 85 patients with LHON, in which it was compared with placebo (a dummy treatment) over 24 weeks. 
Zdravilo Raxone so raziskali v eni glavni študiji, ki je vključila 85 bolnikov z LKON, v kateri so ga 24 tednov primerjali s placebom (zdravilom brez zdravilne učinkovine).
For practical information about using Raxone, patients should read the package leaflet or contact their doctor or pharmacist. 
Za praktične informacije o uporabi zdravila Raxone naj bolniki preberejo navodilo za uporabo ali se posvetujejo z zdravnikom ali farmacevtom.
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Raxone, including the appropriate precautions to be followed by healthcare professionals and patients. 
V skladu s tem načrtom so bile v povzetek glavnih značilnosti zdravila Raxone in navodilo za njegovo uporabo vključene informacije o varnosti, vključno s previdnostnimi ukrepi, ki jih morajo upoštevati zdravstveni delavci in bolniki.
With regard to the safety of Raxone, the majority of side effects seen with the medicine were mild or moderate in intensity. 
Z varnostnega vidika je bila resnost večine neželenih učinkov zdravila Raxone blaga ali zmerna.
Analyses of all these data showed a consistent pattern whereby generally a larger proportion of patients treated with Raxone had vision improvement compared with untreated or placebo-treated patients. 
Analize vseh teh podatkov so pokazale dosleden vzorec, pri katerem je na splošno izboljšanje vida doseglo več bolnikov, zdravljenih z zdravilom Raxone, kot nezdravljenih bolnikov ali bolnikov, ki so prejemali placebo.
How does Raxone work? 
Kako zdravilo Raxone deluje?
Raxone contains the active substance idebenone. 
Zdravilo Raxone vsebuje zdravilno učinkovino idebenon.
How is Raxone used? 
Kako se zdravilo Raxone uporablja?
The results of the main study showed an improvement in vision in patients treated with Raxone, and this trend towards a beneficial effect was confirmed by additional data from an expanded access program and a case record survey. 
Ta koristen učinek so potrdili tudi z dodatnimi podatki iz programa z razširjenim dostopom in raziskave primerov iz evidence.
10 (2 x 5) pre-filled pens 
10 (2 x 5) napolnjenih injekcijskih peresnikov